Pharmaceutical PPC Advertising: Paid Search Rules and Tactics

Search is the one channel in pharma where the audience tells you what they want before you show them anything. Someone typing a drug name plus "side effects" or a symptom plus "treatment" has intent no banner can match. That is why paid search is usually one of the first lines in a DTC plan and one of the last to get cut. It is also a channel with two rulebooks: the platform's and FDA's.

Google Ads rules for pharmaceutical PPC advertising

Google's healthcare and medicines policy restricts promotion of prescription drugs and related services. As of 2026, the main points for US advertisers are:

• Manufacturers. Google allows pharmaceutical manufacturers to advertise prescription drugs in select locations, and the US has historically been one of them. The manufacturer must be certified by Google before ads serve.
• Online pharmacies. They need accreditation from a recognized body (Google lists LegitScript and NABP programs) and Google certification.
• Telemedicine providers. Google points to LegitScript's healthcare merchant certification plus Google certification.
• Prescription drug terms. Their use in keywords, ad text, and landing pages is restricted and varies by country.
• Specific exclusions. Prescription opioid painkillers cannot be promoted, with exceptions for certain treatment providers.

Treat this as a summary, not the policy. Google updates these pages, and Microsoft Advertising has its own healthcare rules. Before any planning, someone on the team should read the current policy page and confirm the account's certification status. Most launch delays I have seen in search come from certification being requested too late, not from MLR.

What FDA rules mean for a 90-character ad

FDA does not have a search-specific rule, but a search ad that names a drug and states what it does is promotional labeling or advertising, and the usual requirements for fair balance and adequate risk information apply. In 2009, FDA sent letters to a number of manufacturers about sponsored search links that included benefit claims without risk information. That episode still shapes how most brands write search copy.

The common approaches are:

1. Name-only branded ads. Drug name, a link to the site, no claim about what it treats. These work like reminder ads. Note that reminder ads are not allowed for drugs with a boxed warning.
2. Branded with indication and risk. Some brands include the indication plus a link or line pointing to important safety information. Fitting this into text ad limits is hard, and regulatory teams differ on what is acceptable.
3. Unbranded disease awareness. Copy about the condition, linking to an unbranded site. No product name, no product claim.

Which approach you use is a regulatory decision. The search team's job is to know the options and bring them to MLR early with real character counts. For broader format rules, see pharmaceutical ads: formats and required elements and fair balance in digital pharma ads.

Branded vs. unbranded keywords

Branded search protects the people who already know the name. Savings card and copay queries are often the highest-value terms in the account because they come from patients close to a fill. Unbranded search is the harder part. It competes with health publishers and health systems for the same queries, and it only pays off if the disease site moves people toward a diagnosis or a conversation.

Landing pages carry most of the compliance load

Because the ad has so little space, the landing page has to do the work. A branded landing page normally shows the indication, important safety information visible without much scrolling (often a persistent ISI tray), and a link to full prescribing information. Unbranded pages must stay unbranded, which means no product logo, colors, or taglines that tie the page back to the drug.

Tracking on these pages is its own review. Search ads drive traffic into a page where people may reveal health conditions, so analytics and ad pixels need privacy review. The tracking pixel governance article covers what to check, and how to evaluate a DTC pharma landing experience covers usability.

Tactics that tend to work

• Separate campaigns for branded, unbranded, competitor, and HCP terms, each with its own budget, so one does not starve another.
• A dedicated HCP campaign pointing to the HCP site, with keywords like dosing, mechanism of action, and prescribing information.
• Negative keyword lists for job seekers, lawsuits, stock price, and unrelated meanings of the drug name.
• Pre-approved ad copy libraries in MLR, so new variants do not wait weeks for review.
• Query report reviews at least monthly, looking for searches that show a safety concern (these may need pharmacovigilance attention, not just a negative keyword).
• Measurement tied to downstream actions, such as savings card downloads or doctor discussion guide use, not clicks alone.

Where search fits in the plan

Search captures demand. It rarely creates it. If TV or CTV is running, branded search volume should rise, and the search budget should be ready to catch it. If there is no upstream awareness, unbranded search is the main way to reach undiagnosed people actively looking for answers. The overall mix logic is in pharmaceutical marketing strategies, and the DTC channel plan in pharmaceutical DTC media strategy.

Practical takeaway

Before the next search budget review, confirm three things in writing: the Google certification status of the account, the MLR-approved copy approach for branded ads (name only, or indication plus risk), and that every landing page has a current ISI and reviewed tracking. If any one of those is unclear, fix it before adding keywords.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.